Tune Therapeutics
Latest round
- Series B
Last raised
- Jan 2025
Total raised
- $160M
Investors
- 7
About Tune Therapeutics
Based in North Carolina, US, and founded in 2020 by Akira Matsuno, Charles Gersbach, and Fyodor Urnov, Tune Therapeutics Inc. develops gene and cell therapies that leverage epigenetic programming for the treatment of genetic diseases and cancers. In January 2025, Tune Therapeutics, Inc. Tune Therapeutics offers a proprietary platform, TEMPO, that operates as an epigenomic therapy to fine-tune gene expression in the emerging class of epitherapeutics.
Who invested in Tune Therapeutics
7 investors across 2 rounds
See all investors in Tune Therapeutics
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Tune Therapeutics
Who invested in Tune Therapeutics?
Tune Therapeutics has 7 investors on record across 2 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Tune Therapeutics raised?
Tune Therapeutics has raised 2 venture rounds. Sign up free to see how much each round raised and the total.
When did Tune Therapeutics last raise money?
Tune Therapeutics's most recent round on record is a Series B, in Jan 2025.
What does Tune Therapeutics do?
Based in North Carolina, US, and founded in 2020 by Akira Matsuno, Charles Gersbach, and Fyodor Urnov, Tune Therapeutics Inc.
Where is Tune Therapeutics headquartered?
Tune Therapeutics is headquartered in Durham, US.
Which VCs invest in companies like Tune Therapeutics?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at Tune Therapeutics's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series B
Raising like Tune Therapeutics? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.